Daiken Medical Co., Ltd. (TYO:7775)
417.00
-6.00 (-1.42%)
Jun 2, 2026, 3:30 PM JST
Daiken Medical Balance Sheet
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash & Equivalents | 2,778 | 2,995 | 2,739 | 2,516 | 2,518 |
Cash & Short-Term Investments | 2,778 | 2,995 | 2,739 | 2,516 | 2,518 |
Cash Growth | -7.25% | 9.35% | 8.86% | -0.08% | 16.04% |
Receivables | 2,570 | 2,471 | 2,479 | 2,530 | 2,431 |
Inventory | 1,591 | 1,430 | 1,438 | 1,514 | 1,544 |
Prepaid Expenses | 30 | 42 | 24 | 18 | 19 |
Other Current Assets | 59 | 47 | 50 | 60 | 60 |
Total Current Assets | 7,028 | 6,985 | 6,730 | 6,638 | 6,572 |
Property, Plant & Equipment | 4,043 | 3,931 | 3,986 | 4,070 | 4,119 |
Long-Term Investments | 67 | 68 | 70 | 65 | 53 |
Other Intangible Assets | 22 | 12 | 13 | 9 | 15 |
Long-Term Deferred Tax Assets | 205 | 183 | 205 | 230 | 160 |
Other Long-Term Assets | 1 | 2 | 2 | 1 | 1 |
Total Assets | 11,366 | 11,181 | 11,006 | 11,013 | 10,920 |
Accounts Payable | 676 | 1,027 | 1,066 | 1,117 | 1,004 |
Accrued Expenses | 76 | 69 | 65 | 70 | 70 |
Short-Term Debt | 939 | 746 | 1,114 | 1,058 | 1,019 |
Current Portion of Long-Term Debt | 470 | 480 | 389 | 659 | 597 |
Current Portion of Leases | 5 | 4 | 8 | 9 | 11 |
Current Income Taxes Payable | 536 | 484 | 671 | 428 | 427 |
Other Current Liabilities | 19 | 19 | 26 | 28 | 23 |
Total Current Liabilities | 2,721 | 2,829 | 3,339 | 3,369 | 3,151 |
Long-Term Debt | 840 | 818 | 623 | 1,013 | 1,280 |
Long-Term Leases | 14 | 3 | 8 | 16 | 26 |
Other Long-Term Liabilities | 15 | 16 | 14 | 19 | 18 |
Total Liabilities | 3,590 | 3,666 | 3,984 | 4,417 | 4,475 |
Common Stock | 495 | 495 | 495 | 495 | 495 |
Additional Paid-In Capital | 400 | 400 | 400 | 400 | 400 |
Retained Earnings | 8,676 | 8,414 | 7,920 | 7,506 | 7,368 |
Treasury Stock | -1,826 | -1,826 | -1,826 | -1,826 | -1,826 |
Comprehensive Income & Other | 31 | 32 | 33 | 21 | 8 |
Shareholders' Equity | 7,776 | 7,515 | 7,022 | 6,596 | 6,445 |
Total Liabilities & Equity | 11,366 | 11,181 | 11,006 | 11,013 | 10,920 |
Total Debt | 2,268 | 2,051 | 2,142 | 2,755 | 2,933 |
Net Cash (Debt) | 510 | 944 | 597 | -239 | -415 |
Net Cash Growth | -45.98% | 58.12% | - | - | - |
Net Cash Per Share | 17.75 | 32.86 | 20.78 | -8.32 | -14.45 |
Filing Date Shares Outstanding | 28.73 | 28.73 | 28.73 | 28.73 | 28.73 |
Total Common Shares Outstanding | 28.73 | 28.73 | 28.73 | 28.73 | 28.73 |
Working Capital | 4,307 | 4,156 | 3,391 | 3,269 | 3,421 |
Book Value Per Share | 270.67 | 261.59 | 244.43 | 229.60 | 224.34 |
Tangible Book Value | 7,754 | 7,503 | 7,009 | 6,587 | 6,430 |
Tangible Book Value Per Share | 269.91 | 261.17 | 243.97 | 229.29 | 223.82 |